



September 4, 2017

✓ **BSE Limited,**
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a press release as regards launch of Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg, for which, USFDA approval was received and are AB rated generic equivalent of Daiichi Sankyo Inc.'s Benicar® tablets.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,
For **LUPIN LIMITED**

R. V. SATAM
COMPANY SECRETARY

Encl.: a.a.



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Lupin launches generic Benicar® tablets in the US

Mumbai, Baltimore, September 04, 2017: Pharma Major Lupin Limited (Lupin) announced the launch of its Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg are the AB rated generic equivalent of Daiichi Sankyo Inc.'s Benicar® tablets. It is indicated for the treatment of hypertension, alone or in combination with other antihypertensive agents, to lower blood pressure.

Benicar® tablets had US sales of USD 681 million (IMS MAT July 2017).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 7th and 6th largest generics pharmaceutical company by market capitalization (June 30th, 2017, Bloomberg) and revenues (March 31st, 2017, Bloomberg) respectively. The Company is the 4th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); 2nd largest Indian pharmaceutical company by global revenues (March 31st, 2017, Bloomberg); 6th largest generic pharmaceutical player in Japan and 6th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT June 2017).

For the financial year ended 31st March, 2017, Lupin's Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter - www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications
Lupin Limited
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225

Arvind Bothra
Head – Investor Relations and M&A
Ph: +91-22-66402137
Email: arvindbothra@lupin.com

**Safe Harbor Statement*

Benicar® is a registered trademark of Daiichi Sankyo Company, Limited.